Literature DB >> 26607397

CRISPR-mediated Activation of Latent HIV-1 Expression.

Prajit Limsirichai1, Thomas Gaj2, David V Schaffer2,3,4,5.   

Abstract

Complete eradication of HIV-1 infection is impeded by the existence of cells that harbor chromosomally integrated but transcriptionally inactive provirus. These cells can persist for years without producing viral progeny, rendering them refractory to immune surveillance and antiretroviral therapy and providing a permanent reservoir for the stochastic reactivation and reseeding of HIV-1. Strategies for purging this latent reservoir are thus needed to eradicate infection. Here, we show that engineered transcriptional activation systems based on CRISPR/Cas9 can be harnessed to activate viral gene expression in cell line models of HIV-1 latency. We further demonstrate that complementing Cas9 activators with latency-reversing compounds can enhance latent HIV-1 transcription and that epigenome modulation using CRISPR-based acetyltransferases can also promote viral gene activation. Collectively, these results demonstrate that CRISPR systems are potentially effective tools for inducing latent HIV-1 expression and that their use, in combination with antiretroviral therapy, could lead to improved therapies for HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26607397      PMCID: PMC4786916          DOI: 10.1038/mt.2015.213

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  99 in total

1.  Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Authors:  Marina Lusic; Alessandro Marcello; Anna Cereseto; Mauro Giacca
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Authors:  Yefei Han; Yijie B Lin; Wenfeng An; Jie Xu; Hung-Chih Yang; Karen O'Connell; Dominic Dordai; Jef D Boeke; Janet D Siliciano; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

5.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

6.  Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Authors:  Qi Zhou; Katharina M Uhlig; Anke Muth; Janine Kimpel; Camille Lévy; Robert C Münch; Janna Seifried; Anett Pfeiffer; Alexandra Trkola; Cheick Coulibaly; Dorothee von Laer; Winfried S Wels; Udo F Hartwig; Els Verhoeyen; Christian J Buchholz
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

8.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

Authors:  E Verdin; P Paras; C Van Lint
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

9.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors.

Authors:  Pablo Perez-Pinera; D Dewran Kocak; Christopher M Vockley; Andrew F Adler; Ami M Kabadi; Lauren R Polstein; Pratiksha I Thakore; Katherine A Glass; David G Ousterout; Kam W Leong; Farshid Guilak; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

10.  Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies.

Authors:  Charles A Gersbach; Thomas Gaj; Carlos F Barbas
Journal:  Acc Chem Res       Date:  2014-05-30       Impact factor: 22.384

View more
  42 in total

1.  Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.

Authors:  Haiyan Ji; Zhengtao Jiang; Panpan Lu; Li Ma; Chuan Li; Hanyu Pan; Zheng Fu; Xiying Qu; Pengfei Wang; Junxiao Deng; Xinyi Yang; Jianhua Wang; Huanzhang Zhu
Journal:  Mol Ther       Date:  2016-01-18       Impact factor: 11.454

Review 2.  Genome-Editing Technologies: Principles and Applications.

Authors:  Thomas Gaj; Shannon J Sirk; Sai-Lan Shui; Jia Liu
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

Review 3.  Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.

Authors:  Tiffany A Peterson; Andrew G MacLean
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-13       Impact factor: 4.147

4.  A CRISPR Approach for Reactivating Latent HIV-1.

Authors:  Angel Lin; Zachary Klase
Journal:  Mol Ther       Date:  2016-03       Impact factor: 11.454

5.  A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.

Authors:  Dawn P Wooley; Priyanka Sharma; John R Weinstein; Poornima Kotha Lakshmi Narayan; David V Schaffer; Katherine J D A Excoffon
Journal:  J Virol Methods       Date:  2017-09-14       Impact factor: 2.014

Review 6.  Gene Editing for Treatment of Neurological Infections.

Authors:  Martyn K White; Rafal Kaminski; Hassen Wollebo; Wenhui Hu; Thomas Malcolm; Kamel Khalili
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 7.  Stem cell-based therapies for HIV/AIDS.

Authors:  Olivier Pernet; Swati Seth Yadav; Dong Sung An
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

Review 8.  Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.

Authors:  Aryn A Price; Arash Grakoui; David S Weiss
Journal:  Trends Microbiol       Date:  2016-02-03       Impact factor: 17.079

Review 9.  HIV cure strategies: which ones are appropriate for Africa?

Authors:  Christopher Zaab-Yen Abana; Helena Lamptey; Evelyn Y Bonney; George B Kyei
Journal:  Cell Mol Life Sci       Date:  2022-07-06       Impact factor: 9.207

Review 10.  CRISPR/Cas technology as a promising weapon to combat viral infections.

Authors:  Carmen Escalona-Noguero; María López-Valls; Begoña Sot
Journal:  Bioessays       Date:  2021-02-11       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.